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Abstract
Purpose—CDK-activating kinase (CAK) is required for the regulation of the cell cycle and is a 
trimeric complex consisting of cyclin-dependent kinase 7 (CDK7), Cyclin H, and the accessory 
protein, MAT1. CDK7 also plays a critical role in regulating transcription, primarily by 
phosphorylating RNA polymerase II, as well as transcription factors such as estrogen receptor-α 
(ER). Deregulation of cell cycle and transcriptional control are general features of tumor cells, 
highlighting the potential for the use of CDK7 inhibitors as novel cancer therapeutics.
Experimental Design—mRNA and protein expression of CDK7 and its essential cofactors 
cyclin H and MAT1 were evaluated in breast cancer samples to determine if their levels are altered 
in cancer. Immunohistochemical staining of >900 breast cancers was used to determine the 
association with clinicopathologic features and patient outcome.
Results—We show that expressions of CDK7, cyclin H, and MAT1 are all closely linked at the 
mRNA and protein level, and their expression is elevated in breast cancer compared with the 
normal breast tissue. Intriguingly, CDK7 expression was inversely proportional to tumor grade and 
size, and outcome analysis showed an association between CAK levels and better outcome. 
Moreover, CDK7 expression was positively associated with ER expression and in particular with 
phosphorylation of ER at serine 118, a site important for ER transcriptional activity.
Conclusions—Expressions of components of the CAK complex, CDK7, MAT1, and Cyclin H 
are elevated in breast cancer and correlate with ER. Like ER, CDK7 expression is inversely 
proportional to poor prognostic factors and survival.
Introduction
Cyclin-dependent kinases (CDK) control cell proliferation by regulating entry into and 
passage through the cell cycle (1). The appropriate action of cell-cycle CDKs is ensured by 
regulation of their activities through the availability of partner cyclins, interaction with CDK 
inhibitors (CDKi), and through their phosphorylation. Phosphorylation at a key threonine 
residue in the activation (T) loop facilitates and/or stabilizes the CDK-cyclin complex (2). In 
metazoans, T-loop phosphorylation is mediated by the CDK-activating kinase (CAK), a 
trimeric complex consisting of CDK7, Cyclin H, and the accessory protein, MAT1. 
Importantly, CDK7 is also required for transcription by phosphorylating the C-terminal 
heptapeptide repeat domain (CTD) of RNA Polymerase II (PolII), a step that is required for 
gene promoter release and transcription initiation by PolII. Importantly, CDK7 also 
modulates regulated gene expression by phosphorylating transcription factors, including p53 
(3), retinoid receptors (4, 5), androgen receptor (AR; refs. 6, 7), and estrogen receptor (ER; 
ref. 8). Ligand-dependent phosphorylation of serine 118 (Ser118), important for ERα 
function and turnover, is mediated by CDK7 (8).
Deregulation of CDK activity by multiple mechanisms, for example, cyclin upregulation and 
mutation, and silencing or loss of genes encoding CDKis or Rb commonly feature in cancer 
(9, 10). Hence, the development of inhibitors of cell-cycle CDKs for cancer treatment has 
received considerable attention, and numerous small-molecule inhibitors have been 
described (11). Surprisingly, genetic studies have indicated that cell-cycle CDKs, with the 
exception of CDK1, are not essential for most cell types (12, 13). Nevertheless, following an 
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initial disappointment with several candidate drugs, newer CDK-selective inhibitors have 
offered renewed optimism in the utility of these targets. In particular, CDK4/6-selective 
inhibitors have shown promise against a broad range of cancers, including breast cancer, but 
can be ineffective, for example, where Rb is absent or inactivated (14, 15). In addition, 
CDK4/6 inhibitors are efficacious in combination with hormone therapies, for the treatment 
of ERα-positive advanced breast cancer (16).
Transcription inhibition appears to be important for the antitumor activities of several broad 
range small molecule inhibitors of CDKs, such as flavopiridol and seliciclib, which inhibit 
CDK7 and CDK9 (phosphorylation of PolII by CDK9 is needed for transcription 
elongation), in addition to inhibiting other CDKs. The action of these drugs has been linked 
to a reduction in PolII phosphorylation and reduced expression of short-lived antiapoptotic 
proteins, such as Mcl-1 and XIAP, to promote apoptosis (15). The dual role of CDK7 in 
transcription and the cell cycle means that CDK7 inhibitors potentially provide a potent 
means of blocking cell-cycle progression, together with the promotion of apoptosis by 
transcription inhibition in cell lines from a variety of cancer types, including breast, 
leukemia, neuroblastoma, and lung (17–20). In the latter tumor types, the effects of CDK7 
on RUNX1 and MYC expression and function are critical factors in the action of CDK7 
inhibition. A further reason for CDK7 as a cancer target is that, although required for early 
embryonic development, CDK7 was not found to be essential in adult tissues with low 
proliferative indices (21), indicating that CDK7-selective inhibitors might not show general 
toxicity in cancer patients.
We have investigated the expression of CDK7 in breast cancer, because this might further 
support the case for the use of CDK7-selective inhibitors for cancer therapy, particularly in 
this tumor type. By profiling expression of the components of the CAK complex, CDK7, 
Cyclin H, and MAT1 in the normal and malignant breast, we demonstrate that their 
expression is coordinately elevated in breast cancer, especially in ER-positive tumors, 
compared with normal breast tissue. We also show that CDK7, cyclin H, and MAT1 
expression is correlated with ER levels and is related to a good patient prognosis.
Materials and Methods
Breast cancer samples
Tumor and surrounding normal tissue: Tissue samples (snap frozen) were obtained from 
patients undergoing breast surgery between 2011 and 2013; all patients gave their consent 
according to the tissue bank protocol (see below). Samples of tumor tissue and surrounding 
morphologically normal tissue, taken >5 cm from the tumor, were obtained from each 
patient. All samples were obtained from the Barts Cancer Institute Breast Tissue Bank and 
were covered by Research Tissue Bank Ethics Approval. RNA was also prepared from 
tumors from 74 patients who presented with primary, operable breast cancer to the Dundee 
Cancer Centre between 1997 and 2012 and provided written, informed consent for research 
use of their tissues; the Tayside Tissue Bank under delegated authority from the Tayside 
Local Research Ethics Committee approved the use of the clinical material and data. ER 
immunohistochemical staining and scoring were carried out as described (22). Tissue 
microarrays (TMA) were prepared from a series of primary operable breast cancer 
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carcinoma cases from 1986 to 1999 aged 70 years or less at the Nottingham Breast Unit. 
Patient selection and treatment details have been reported previously (23, 24).
RNA preparation and quantitative RT-PCR
A total of 50 to 100 mg of frozen tissue was homogenized using TissueLyser (Qiagen) with 
stainless steel ball bearings (5 mm) in 0.7 mL of lysis/binding buffer and the total RNA 
extracted using an RNeasy kit (Qiagen) according to the manufacturer's instructions. RNA 
purity and concentration were measured using a Nanodrop 1000 spectrophotometer (Nano-
drop Technologies). cDNA was prepared by reverse transcription of 2.0 μg of total RNA, in 
a final volume of 20 μL using RevertAid M-MuLV reverse transcriptase (Fermentas) and 
random hexamer oligonucleotide priming. Quantitative gene expression analysis was carried 
out using real-time PCR and Taqman gene expression assays for CDK7 (Hs00361486_m1), 
Cyclin H (Hs00236923_m1), MAT1 (Hs01041574_m1), and GAPDH (Hs99999905_m1; 
Life Technologies). Gene expression was normalized to GAPDH expression using the 
2−ΔΔCT method (25).
Gene expression and correlation analysis of microarray data
Expression of CDK7, Cyclin H, and MAT1 was analyzed in normal breast (n = 144) and 
breast cancer (n = 1,556) samples from the METABRIC dataset using Oncomine (26). For 
the expression of ER, CDK7, Cyclin H, MAT1, and PGR in the METABRIC dataset of 
patient samples (n = 1,959), median expression was used as the cutoff in a Cox regression 
analysis. Kaplan–Meier survival plot, HR with 95% confidence intervals, log-rank P value, 
and correlation scores (Pearson and Spearman) were calculated and plotted in R using 
Bioconductor packages.
Immunohistochemistry
Mouse monoclonal antibodies for CDK7 (ab115181; Abcam), cyclin H (ab54903; Abcam), 
and MAT1 (sc-135981; Santa Cruz Biotechnology) were used for immunohistochemistry 
(IHC) at a working dilution of 1:100 in Leica antibody diluent. The staining methodology 
has been described previously (24). Immunohistochemical detection of ER phosphorylated 
at serine 118 (P-Ser118) was carried out as detailed before (27). Immunostaining was 
assessed using the H-scoring method, and the X-tile software (28) was used to produce 
cutoff points for low and high expression levels, as described (24). In brief, this involved 
random assignment of the patient cohort into two separate training and validation groups 
ranked by the patient follow-up time. Checking the obtained cutoff points to the validation 
set tested statistical significance. IHC and scoring for all other proteins have previously been 
described (29, 30).
Statistical analyses
Statistical analysis of IHC scores for the breast cancer TMAs was performed using SPSS 21 
software (SPSS Inc.). The association between CDK7, Cyclin H, and MAT1 and 
clinicopathologic parameters was determined using the Pearson χ2 test. Survival curves 
were estimated by the Kaplan–Meier method with a log-rank test to assess the significance. 
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Multivariate Cox proportional hazard regression models were used to determine independent 
prognostic effect of variables.
siRNA transfections
MCF-7 cells were transfected with siRNA using the lipofectamine RNAiMAX reverse 
transfection protocol (Life Technologies), as described previously (31). siRNAs for CDK7 
(s2829, s2830), Cyclin H (s2537 and s2538), MAT1 (s8898 and s8900), and nontargeting 
(control) siRNA (4390844) were obtained from Life Technologies. Forty-eight hours after 
transfection, cells were lysed in RIPA buffer. Immunoblotting was carried out using 
antibodies for CDK7 (ab9516), Cyclin H (ab54903), and ß-actin (ab6276), purchased from 
Abcam, as described previously (31). Antibodies for MAT1 (sc-13598), TBP (sc-421), and 
P-Ser118 (sc-12915) were purchased from Santa Cruz Biotechnology and ER (VP-E614) 
from Vector Laboratories. For performing qRT-PCR, MCF-7 cells were transfected with 
siRNAs for CDK7, Cyclin H, and MAT1, purchased from Dharmacon. Total RNA was 
prepared using the RNeasy Kit according to the manufacturer's methods (Qiagen).
Results
CDK7, Cyclin H, and MAT1 are overexpressed in breast cancer
To compare CDK7 expression in normal and malignant breast tissue, we prepared total RNA 
from 20 breast cancers and matched adjacent normal breast tissue (Fig. 1A–C; 
Supplementary Fig. S1A–S1C). CDK7 was detectable in all samples at the mRNA level. 
Interestingly, the majority of tumors were characterized by higher CDK7 expression, 
compared with the matched adjacent normal tissue. Mean CDK7 expression was 2.2-fold 
higher in tumors, compared with the adjacent normal tissue (P = 0.006). Cyclin H and 
MAT1 expression was similarly elevated in breast cancer, Cyclin H (P = 0.0061) and MAT1 
(P = 0.0057) levels in tumors being 1.9- and 2.1-fold higher, respectively, than in the normal 
breast. Epithelial cell adhesion molecule (EpCAM) is an epithelial marker, the expression of 
which can be elevated in breast cancer (32). EpCAM mRNA levels were not significantly 
different in our samples (Supplementary Fig. S1D), indicating that the elevated CDK7 
expression in this series is unlikely to be due to lower epithelial cellularity of the adjacent 
normal tissue. IHC of a small series of breast cancer samples showed that nuclear CDK7 
immunostaining intensity was consistently higher in tumor cells, compared with CDK7 
levels in adjacent normal elements (Supplementary Fig. S1E and S1F). Cyclin H levels were 
also elevated in tumor cells compared with adjacent normal elements. However, MAT1 
levels were not different between normal and cancer cells.
We next analyzed CDK7, Cyclin H, and MAT1 expression in the METABRIC microarray 
dataset of 1,556 breast cancers and 144 normal breast samples (33). As observed by qRT-
PCR in our samples, CDK7 (P = 1.49 × 10−38), Cyclin H (P = 9.41 × 10−4), and MAT1 (P = 
9.06 × 10−10) expression was also elevated in breast cancer, compared with expression in 
normal breast in this data set (Fig. 1D).
Interestingly, these analyses indicated that expression of CDK7, Cyclin H, and MAT1 may 
be coregulated (for example, see patient samples 1, 2, 10, and 11; Supplementary Fig. S1A–
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S1C). Pairwise comparison using Pearson correlation coefficient analysis showed that the 
expression of CDK7 and Cyclin H is indeed strongly associated in this tumor series (r2 = 
0.861; P < 0.0001), as is the expression of CDK7 and MAT1 (r2 = 0.879; P < 0.0001) and 
Cyclin H and MAT1 (r2 = 0.862; P < 0.0001; Supplementary Fig. S2A–S2C). In agreement 
with this, Pearson correlation coefficient analysis of the 1,959 samples in the METABRIC 
cohort showed evidence of a relationship between expression of CDK7 and Cyclin H (r2 = 
0.28), CDK7 and MAT1 (r2 = 0.25), and an especially strong association between Cyclin H 
and MAT1 expression (r2 = 0.69; Supplementary Fig. S2D). The difference in strength of 
associations in our cohort and METABRIC may reflect, at least in part, differences in 
proportions of different breast cancer subtypes. Indeed, 63% (47/74) of tumors in our cohort 
are ER-positive, compared with 77% (1,489/1,928) of the samples in METABRIC. Analysis 
of The Cancer Genome Atlas and other breast cancer data sets showed that mutations, 
amplification, and/or deletion of the CDK7, cyclin H, and/or MAT1 genes are uncommon 
(Supplementary Fig. S2E), so their elevated expression and/or coregulation are unlikely to 
be the result of gene rearrangement.
To determine if coregulation of the CDK7, Cyclin H, and MAT1 genes can be confirmed 
experimentally in breast cancer cells, we performed siRNA for CDK7 in MCF-7 cells. 
Efficient CDK7 knockdown was achieved at both the mRNA and protein levels (Fig. 1E and 
H). In addition, siCDK7 transfection also resulted in Cyclin H and MAT1 downregulation at 
the mRNA and protein levels (Fig. 1F–H). Similarly, transfection of MCF-7 cells with 
Cyclin H siRNA led to reductions in Cyclin H, but also reductions in the levels of CDK7 and 
MAT1 mRNA and protein. Finally, MAT1 siRNA reduced not only MAT1, but also CDK7 
and Cyclin H expression. By contrast, expression of the TFIIH p62 subunit was unaffected, 
as were TBP and ER levels, suggesting that the siRNA-mediated reduction in CAK 
expression is specific. In agreement with our findings, reduction in protein levels of all three 
CAK subunits has been reported for CDK7 and MAT1 knockout mice (21, 34). What is 
striking from our results is that knockdown of one CAK subunit not only results in reduction 
in protein levels of the other subunits, which might be attributable to disruption of the CAK 
complex, rather mRNA levels of the other subunits are reduced, implicating transcriptional 
or posttranscriptional mechanisms in the co-ordinate regulation of CAK subunit mRNA 
levels. Finally, immunoblotting of MCF7 cells sorted by flow cytometry showed similar 
expression patterns for CDK7, cyclin H, and MAT1 through the cell cycle, with highest 
levels of each subunit in G1 and G2–M (Supplementary Fig. S3A and S3B). siRNA-
mediated knockdown of CDK7 was not associated with cell-cycle arrest, but resulted in 
apoptosis (Supplementary Fig. S3C), as has been described for CDK7 inhibitors BS-181 and 
THZ1 (17, 18).
CDK7, Cyclin H, and MAT1 expression is associated with better patient outcome in breast 
cancer
In order to determine expression of the CAK complex proteins in breast cancer and to 
analyze associations with clinical features, we carried out IHC of breast cancer TMAs for 
CDK7 (n = 945), Cyclin H (n = 1,218), and MAT1 (n = 910; Fig. 2A). Differential staining 
was evident for different samples, so the H-scoring method and cutoff H-scores were used to 
segregate tumors into high and low expression groups. Spearman Rank correlation of protein 
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levels for the CAK subunits (H-scores) showed that expression of CDK7, Cyclin H, and 
MAT1 is strongly associated (P < 0.001; Fig. 2B), as was observed for mRNA levels, further 
evidence for an important relationship between expression of the three CAK subunits in 
breast cancer.
There was a suggestion of an association of CDK7 expression with age in patients ages 
between 51 and 60 (P = 0.042), but not with menopausal status (P = 0.39; Table 1). High 
MAT1 levels were also weakly associated with age (P = 0.044), but not with menopausal 
status (P = 0.22). Importantly, elevated expression of CDK7, Cyclin H, and MAT1 was 
associated with markers of better prognosis. Hence, patients with high grade and larger 
tumors, or those who developed recurrent disease, featured low CDK7, Cyclin H, and/or 
MAT1 expression. As expected from the association of high levels of the CAK components 
with low tumor grade and reduced recurrence, high CDK7 expression was associated with 
longer breast cancer–specific survival (BCSS; log-rank = 4.11, P = 0.04; Fig. 2C). 
Multivariate Cox hazard analysis, including tumor stage, size, grade, and lymph node (LN) 
status, showed an increased significance of CDK7 with longer BCSS [HR, 0.65 (0.41–0.84), 
P = 0.001; Table 2]. Multivariate analysis also showed a benefit for high CDK7 expression 
for time to distant metastasis (TTDM; Supplementary Table S1). High Cyclin H (log-rank = 
7.32; P = 0.007) and MAT1 (log-rank = 8.43; P = 0.004) were also associated with longer 
BCSS. Univariate analysis for low or high expression of all three CAK subunits maintained 
the survival benefit (log-rank = 6.09; P = 0.014). In the multivariate analysis model, tumor 
size, LN status, and HER2 status, along with BCSS, were significantly associated with high 
Cyclin H (P = 0.003) and MAT1 expression (P = 0.016), as was high expression of all three 
proteins (CAK; P = 0.001; Table 2; Supplementary Table S1).
Expression levels of the CAK subunits are associated with ER expression in breast cancer
Interestingly, CDK7 (P = 0.001), Cyclin H (P < 0.001), and MAT1 (P < 0.001) levels were 
higher in ER-positive than in ER-negative breast cancer (Table 3), and there was a positive 
association of CDK7 (P = 0.002), Cyclin H (P < 0.001), and MAT1 (P < 0.001) levels with 
PGR positivity, together indicative of higher CAK levels in luminal breast cancer. This was 
further confirmed by the fact that CDK7, cyclin H, and MAT1 levels were associated with 
AR positivity, as AR expression is strongly associated with ER (35, 36). There was also a 
significant association with the luminal A marker, GATA3 (37), although there was an 
inverse relationship with FOXA1, another important marker of luminal A breast cancer. 
Indeed, CDK7, Cyclin H, and MAT1 levels were lower in HER2-positive than in HER2-
negative breast cancer and in triple-negative (TN) breast cancer, compared with non-TN 
breast cancer.
Real-time RT-PCR analysis of RNAs prepared from 74 independent breast cancers showed 
that CDK7 mRNA levels are also positively associated with ER mRNA levels (r2 = 0.56; P < 
0.0001; Supplementary Fig. S4A), as are Cyclin H (r2 = 0.46; P < 0.0001) and MAT1 (r2 = 
0.44; P < 0.0001) mRNA levels. As expected, a relationship between ER and PGR mRNA 
levels (r2 = 0.63; P < 0.0001) was also observed in this patient series. The association was 
also evident when comparing CDK7, Cyclin H, and MAT1 mRNA levels with 
immunohistochemically defined ER status in this sample set (Supplementary Fig. S4B and 
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S4C). Further confirming this association, CDK7, Cyclin H, and MAT1 mRNA expression 
was also positively associated with ER mRNA levels in the METABRIC dataset 
(Supplementary Fig. S4D). Analysis of the CAK expression in the PAM50 breast cancer 
subtypes showed slightly higher expression in luminal B than in luminal A breast cancer; P 
= 0.03, 0.02, and <2.2e–16 for CDK7, cyclin H, and MAT1, respectively (Supplementary 
Fig. S4E–S4G). Moreover, CAK expression was significantly higher in luminal A/B than in 
HER2+ or in basal breast cancer. Interestingly, expression of each of the CAK subunits was 
also higher in HER2-positive than in basal breast cancer.
Taken together, the simplest explanation for the high expression of CAK in ER-positive 
breast cancer is that ER regulates their expression. However, treatment of MCF-7 cells with 
estrogen did not affect expression of any of the subunits (Supplementary Fig. S5A). 
Furthermore, ER knockdown did not affect CAK levels (Supplementary Fig. S5B). 
Examination of ER ChIP-seq for MCF7 cells (38), did not identify ER binding regions 
within the genes, nor within 50 kb 5′ or 3′ to the CDK7, Cyclin H or MAT1 genes. 
Together, these results indicate that the association between expression of the CAK genes 
and ER expression is not due to direct regulation by ER. Interestingly, high expression of the 
CAK complex in our TMA series was associated with longer TTDM (log-rank = 6.68; P = 
0.01) and BCSS in ER-positive breast cancer (log-rank = 5.61; P = 0.018; Fig. 2D and E).
Evidence for a role of CDK7 in phosphorylation of ER at serine 118 in breast cancer
Phosphorylation of ER at serine 118 (Ser118) promotes ER activity, CDK7 has been shown 
to mediate ligand-dependent phosphorylation of Ser118 (8, 39), and CDK7 knock-down 
resulted in reduction in Ser118 phosphorylation (Fig. 1H). To determine if Ser118 
phosphorylation is related to CDK7 expression in breast cancer, we performed IHC for ER 
phosphorylated at Ser118 (P-Ser118). In agreement with previous findings linking Ser118 
phosphorylation with better prognosis (40), Ser118 phosphorylation was associated with 
better TTDM and BCSS, high P-Ser118 levels being correlated with better survival. Patients 
with intermediate P-Ser118 had worse prognosis, and patients with very low/absent P-
Ser118 had the poorest survival (TTDM log-rank = 19.9, P < 0.001; BCSS log-rank = 13.0, 
P = 0.005; Supplementary Fig. S3).
More than half (54.1%) of the CDK7-low breast cancers were negative or were weakly 
positive for P-Ser118, compared with just 26.2% of the CDK7-high tumors (P < 0.001; χ2 = 
56.3; Table 4). As expected, similarly strong associations were obtained for P-Ser118 and 
Cyclin H (P < 0.001; χ2 = 43.8), and P-Ser118 and MAT1 (P < 0.001; χ2 = 66.5).
Discussion
The importance of CDK7 in cell-cycle regulation and transcription has highlighted this 
kinase as a potential therapeutic target for cancer treatment. In line with this, recently 
described CDK7-selective inhibitors show antitumor activity in several cancer models (17–
20). Importantly, these studies show that transcriptional drivers that are especially important 
in specific cancer types, for example, RUNX1 in leukemia, are particularly sensitive to 
CDK7 inhibition (18). Similarly, particular sensitivity of the MYCN (neuroblastoma; ref. 
20) and MYC (lung cancer; ref. 19) genes to CDK7 inhibition has been described and 
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appears to be due to hypersensitivity of super-enhancers that drive expression of these 
factors. Given this diverse range of tumor types that potentially respond, we wanted to 
determine if CDK7 expression is altered in cancer, as expression and activity may be 
important factors in the utility of CDK7 inhibitors in the clinic. We chose to investigate 
CDK7 expression in breast cancer, since we have previously shown that a selective CDK7 
inhibitor, BS-181, inhibits breast cancer cell growth in vitro and in vivo (17). Moreover, 
CDK7 directly regulates the transcriptional activity of ER by phosphorylating Ser118 (8, 
39); thus, CDK7 inhibitors might be especially effective in ER-positive breast cancer 
featuring elevated Ser118 phosphorylation.
Comparison of breast cancers with matched adjacent normal tissue showed that CDK7 
mRNA levels are elevated in this tumor type. This was confirmed by analysis of microarray 
datasets and is in agreement with previous reports which suggested that CDK7 protein levels 
are higher in cancer compared with the normal breast (41, 42). It is possible that these 
observations reflect differences in epithelial cell content. However, real-time RT-PCR for 
EpCAM, as well as comparison of CDK7 IHC for normal breast with CDK7 levels in tumor 
samples, indicates that CDK7 levels are indeed elevated in breast cancer. Mutations and 
gene rearrangements at the CAK gene loci are uncommon, so this is unlikely to represent a 
major mechanism for high expression in breast cancer. Interestingly, the CDK7 and Cyclin 
H genes are located 18 Mb apart on human chromosome 5 and are also linked in the 
genomes of several other vertebrates, including Zebrafish, chicken, rodents, and man, 
making coregulation through common gene regulatory elements possible.
Remarkably, we observed that mRNA and protein levels of Cyclin H and MAT1, both of 
which are required for CDK7 activity, are also increased in breast cancer, indicative of 
upregulation of CAK activity in breast cancer. siRNA experiments also showed that 
knockdown of any one CAK subunit resulted in reduced expression of the other subunits, 
implying coregulation of the expression of the CAK complex at the transcriptional level. 
Although the exact mechanisms underlying this coregulation remain unclear, treatment with 
the CDK7 inhibitor BS-181 resulted in reduced CDK7 protein levels (17) and THZ1, a 
covalent CDK7 inhibitor, inhibits PolII recruitment to gene promoters (18), indicating that 
expression of the CAK complex is strongly linked to CDK7 activity. It is possible that this 
coregulation is due to loss of CAK subunits in apoptotic cells. Notwithstanding, IHC 
staining of >900 breast cancers also demonstrated a significant association between levels of 
CDK7, Cyclin H, and MAT1, which, together with the association for mRNA expression of 
the CAK subunits, provides strong evidence for coregulation of CAK subunit expression in 
breast cancer.
Interestingly, high-level expression of each of the CAK subunits was associated with longer 
survival in univariate and multivariate analyses. The relationship between CDK7 and 
prognosis in breast cancer seems analogous to the relationship between ER and prognosis, in 
that ER confers a good prognosis, but is at the same time a suitable target for therapy. 
Moreover, the majority of tumors with high CDK7 levels were ER-positive, as were tumors 
with high levels of Cyclin H and MAT1. In agreement with this, real-time RT-PCR and 
analysis of the METABRIC microarray datasets showed positive associations between 
mRNA levels of each CAK subunit with ER mRNA levels, as well as ER status. In ER-
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positive breast cancer, CAK expression was also associated with better prognosis. This does 
not appear to be due to higher CAK expression in luminal A compared with luminal B 
breast cancer. Indeed, in METAB-RIC, CAK transcript levels are similar to, or higher in, 
luminal B than in luminal A breast cancer. The mechanisms underlying the association 
between CDK7, Cyclin H, and MAT1 expression and ER are unclear, but it is interesting to 
note that CAK levels were strongly associated with ER phosphorylation at Ser118, which 
provides in vivo evidence for the previously described role of CDK7 in phosphorylating this 
residue (8). Ser118 phosphorylation is important not only for stimulating ER activity, but 
also regulates ER degradation and consequently ER levels (43, 44). This might afford a 
potential explanation for the relationship between levels of CAK and ER protein in breast 
cancer. Moreover, ER positively regulates its own gene expression, at least in part through a 
positive cross-regulatory loop with GATA-3 mRNA levels (45). CDK7 may thus promote 
ER gene expression by stimulating its activity through phosphorylation of Ser118. 
Alternatively, transcription of the ER gene may be particularly sensitive to CDK7 activity, as 
demonstrated by the sensitivity of the RUNX1 and MYC genes in other cancers (18).
We previously reported the first specific, small-molecule CDK7 inhibitor, BS-181 (17). We 
showed that BS181 promotes p53-dependent and independent apoptosis, at least in part by 
inhibiting the expression of short-lived transcripts for genes encoding inhibitors of 
apoptosis. The additional work presented here shows that CAK siRNA reduces ER 
phosphorylation, in line with its known action on ER phosphorylation at Ser118 (8). Our 
findings, therefore, offer some explanation as to why CDK7 expression carries a good 
prognosis in patients with ER-positive breast cancer, in that in our sets, these patients have 
been treated with adjuvant endocrine therapy, where improved survival is dependent on a 
functioning ER, for which Ser118 phosphorylation is critical.
In summary, CDK7, Cyclin H, and MAT1 mRNA and protein levels are elevated in breast 
cancer, particularly in ER-positive breast cancer. Given the importance of CDK7 in 
regulation of transcription, as well as its role in the direct regulation of ER activity through 
phosphorylation of Ser118, our findings support the potential use of CDK7 inhibitors in the 
treatment of ER-positive breast cancer, either as a single agent or in combination with 
hormonal therapy, with perhaps the most suitable group for treatment being ER-positive 
breast cancer patients with high CDK7 and P-Ser118 levels.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
Cyclin-dependent kinase 7 (CDK7) is a critical regulator of cell-cycle progression and 
gene expression, processes that are frequently deregulated in cancer. As such, inhibition 
of CDK7 activity has been proposed as a therapeutic strategy for the treatment of cancer, 
an aim that is supported by the recent development of selective CDK7 inhibitors with 
potent anti-cancer activities. Since CDK7 is centrally involved in key cellular processes 
in all cells, the use of CDK7 inhibitors could be limited by a toxicity associated with its 
function in normal tissues. Using mRNA expression profiling and immunohistochemistry, 
we find that expression of CDK7, as well as the associated cofactors Cyclin H and 
MAT1, are all elevated in breast cancer, suggesting that this tumor type may be especially 
sensitive to CDK7 inhibition and that the CDK7 overexpression may allow mitigation of 
toxicity seen in normal tissues.
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Figure 1. 
CDK7, Cyclin H, and MAT1 mRNA levels are elevated in breast cancer and show evidence 
of coordinate regulation. A–C, CDK7, Cyclin H, and MAT1 mRNA levels, determined by 
real-time RT-PCR analysis, were normalized to the expression of GAPDH for RNA prepared 
from 20 paired tumor and adjacent normal tissues. D, Analysis of microarray data from the 
METABRIC samples for expression of CDK7, Cyclin H, and MAT1 in normal breast and 
breast cancer samples. E–G, MCF-7 cells were transfected with two independent siRNAs 
for CDK7, Cyclin H, and MAT1. Real-time RT-PCR was performed using RNA prepared 48 
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hours after transfection. CDK7, Cyclin H, and MAT1 expression is shown relative to 
expression of GAPDH for three independent samples. Expression of all three genes was 
significantly reduced (P < 0.001) for each siRNA when compared with the control siRNA. 
H, Immunoblotting was performed using protein lysates prepared following siRNA 
transfection as above.
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Figure 2. 
Immunohistochemical analysis of CDK7, Cyclin H, and MAT1 expression in breast cancer. 
CDK7, Cyclin H, and MAT1 antibodies were used to immunostain breast cancer TMAs. The 
sections were scored as CDK7 low (H-score: 0–160), CDK7 high (H-score: 161–300), 
Cyclin H low (H-score: 0–194), Cyclin H high (H-score: 195–300), MAT1 low (H-score: 0–
179), or MAT1 high (H-score: 180–300). Negative controls were performed by omitting the 
primary antibody. A, Staining representative of low and high H-scores is shown. B, 
Pearson's correlation analysis is shown, together with r2 values for each pair-wise 
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comparison. C, Kaplan–Meier plots showing BCSS for CDK7, Cyclin H, and MAT1 
expression in breast cancer. D, COX regression analysis for TTDM and BCSS for ER-
positive breast cancer samples only. E, Kaplan-Meier plot of high versus low CAK levels in 
ER-positive breast cancer.
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Table 1
CDK7, CycH, and MAT1 expression and clinicopathologic associations
Variable
CDK7 expression (%) CycH expression (%) MAT1 expression (%)
Low
(0 –160)
High
(161–300) P
Low
(0–194)
High
(195–300) P
Low
(0 –179)
High
(180 –300) P
Age
   <40 16 (5.9) 65 (9.7) 0.042 59 (9.7) 46 (7.6)   0.34 38 (8.6) 40 (8.7)   0.044
   41–50 72 (26.8) 172 (25.6) 159 (26.2) 167 (27.6) 111 (25.2) 130 (28.1)
   51–60 100 (37.2) 198 (29.5) 198 (32.6) 182 (30) 158 (35.8) 126 (27.3)
   >60 81 (30.1) 236 (30.1) 192 (31.6) 211 (34.8) 134 (30.4) 166 (35.9)
Menopausal status
   Pre 100 (37.6) 259 (38.9) 0.39 237 (39.4) 238 (39.5)   0.97 162 (37.1) 189 (41.1)   0.22
   Post 166 (62.4) 407 (61.1) 365 (60.6) 365 (60.5) 275 (62.9) 271 (58.9)
Tumor size (cm)
   <2.0 121 (44.8) 326 (48.9) 0.28 273 (45) 307 (50.6)   0.051 185 (42) 246 (53.7) <0.001
   ≥2.0 149 (55.2) 341 (51.1) 334 (55) 300 (49.4) 255 (58) 212 (46.3)
Grade
   1 36 (13.4) 98 (14.7) 0.16 84 (13.9) 109 (18) <0.001 53 (12.1) 85 (18.6) <0.001
   2 82 (30.5) 239 (35.9) 174 (28.7) 229 (37.9) 118 (26.9) 176 (38.4)
   3 151 (56.1) 328 (49.3) 348 (57.4) 266 (44) 268 (61) 197 (43)
LN
   Negative 186 (68.9) 382 (57.2) 0.001 382 (62.9) 363 (59.8)   0.26 286 (65) 264 (57.5)   0.021
   Positive 84 (31.1) 286 (42.8) 225 (37.1) 244 (40.2) 154 (35) 195 (42.5)
Local recurrence
   No 210 (79.2) 555 (84.3) 0.07 501 (84.1) 486 (82.5)   0.48 355 (81.8) 376 (83.2)   0.59
   Yes 55 (20.8) 103 (15.7) 95 (15.9) 103 (17.5) 79 (18.2) 76 (16.8)
Regional recurrence
   No 212 (80) 576 (77.5) 0.003 510 (85.6) 516 (87.6)   0.3 351 (80.9) 399 (88.3)   0.002
   Yes 53 (20) 82 (22.5) 86 (14.4) 73 (12.4) 83 (19.1) 53 (11.7)
Distant metastasis
   No 149 (55.2) 417 (62.4) 0.04 373 (61.6) 388 (64.1)   0.35 251 (56.9) 304 (65.9)   0.005
   Yes 121 (44.8) 251 (37.6) 233 (38.4) 217 (35.9) 190 (43.1) 157 (34.1)
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Table 2
Multivariate Cox regression analysis for BCSS
Variable P HR (95% CI)
Tumor size   0.002 1.48 (1.15–1.90)
Stage <0.001 1.97 (1.65–2.35)
Grade <0.001 1.78 (1.45–2.19)
HER2 <0.001 1.69 (1.26–2.26)
CDK7   0.001 0.65 (0.51–0.84)
Tumor size   0.001 1.49 (1.18–1.88)
Stage <0.001 1.91 (1.65–2.23)
Grade <0.001 1.85 (1.54–2.23)
HER2 <0.001 1.67 (1.28–2.20)
CycH   0.003 0.72 (0.58–0.90)
Tumor size   0.049 1.28 (1.01–1.63)
Stage <0.001 1.82 (1.53–2.16)
Grade   0.001 1.38 (1.15–1.66)
HER2   0.001 1.66 (1.24–2.23)
MAT1   0.016 0.75 (0.59–095)
Tumor size   0.002 1.82 (1.25–2.65)
Stage <0.001 1.95 (1.50–2.53)
Grade   0.10 1.29 (0.95–1.76)
HER2   0.002 2.09 (1.32–3.32)
CAK   0.001 0.53 (0.37–0.78)
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Table 3
Relationship between CDK7, Cyclin H, and MAT1 expression and breast cancer subtypes
CDK7 Cyclin H MAT1
Variable
Low
(0–160)
High
(161–300)
P
(χ2)
Low
(0–194)
High
(195–300)
P
(χ2)
Low
(0–179)
High
(180–300)
P
(χ2)
ER
    Negative 87 (32.2) 148 (22.2)   0.001 194 (32.1) 117 (19.4) <0.001 151 (34.2) 93 (20.3) <0.001
    Positive 183 (67.8) 520 (77.8)   (10.4) 410 (67.9) 486 (80.6)   (25.5) 291 (65.8) 365 (79.7)   (21.9)
PGR
    Negative 128 (49.2) 248 (38.3)   0.002 292 (49.6) 191 (33) <0.001 214 (49.7) 157 (35.7) <0.001
    Positive 132 (50.8) 400 (61.7)   (9.2) 297 (50.4) 388 (67)   (33.1) 217 (50.3) 283 (64.3)   (17.4)
ER/PGR status
    ER+/PGR+ 132 (50.8) 400 (61.7)   0.003 295 (50.3) 387 (67.1) <0.001 217 (50.3) 282 (64.4) <0.001
    ER+/PGR− 46 (17.7) 108 (16.7)   (11.4) 104 (17.7) 80 (13.9)   (35.4) 68 (15.8) 71 (16.2)   (25.6)
    ER−/PGR− 82 (31.5) 140 (21.6) 187 (31.9) 110 (19.1) 146 (33.9) 85 (19.4)
AR
    Negative 125 (52.7) 199 (33.2) <0.001 249 (46.5) 155 (28.9) <0.001 179 (46.9) 120 (29.3) <0.001
    Positive 112 (47.3) 400 (66.8)   (27.3) 287 (53.5) 381 (71.1)   (35.1) 203 (53.1) 290 (70.7)   (26.0)
FOXA1
    Negative 67 (34.7) 209 (48.5)   0.001 154 (37.6) 199 (52.5) <0.001 119 (36.1) 150 (52.8) <0.001
    Positive (≥10) 126 (65.3) 222 (51.5)   (10.3) 256 (62.4) 180 (47.5)     (17.8) 211 (63.9) 134 (47.2)   (17.4)
GATA3
    Negative/low (<60) 154 (87.5) 277 (71.9) <0.001 310 (83.8) 229 (70.2) <0.001 245 (86) 177 (67.3) <0.001
    Positive (≥60) 22 (12.5) 108 (28.1)   (16.4) 60 (16.2) 97 (29.8) (18.2) 40 (14) 86 (32.7)   (26.9)
HER2
    Negative 212 (81.2) 566 (87.5)   0.015 506 (86.3) 500 (86.8)   NS 350 (81.4) 394 (90) <0.001
    Positive 49 (18.8) 81 (12.5)   (5.9) 80 (13.7) 76 (13.2) 80 (18.6) 44 (10)   (13.0)
TN
    Non-TN 207 (87.7) 554 (84.6)   0.033 453 (76.3) 523 (88.5) <0.001 329 (76.3) 390 (87.1) <0.001
    TN 56 (21.3) 101 (15.4)   (4.6) 141 (23.7) 68 (11.5)   (30.5) 102 (23.7) 58 (12.9)   (16.9)
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Table 4
Phosphorylation levels of ER Serine 118 are associated with CDK7, CycH, and MAT1 levels
P-Ser118-ER
Variable
Negative
(0–50)
Low
(51–100)
Moderate
(101–200)
High
(201–300)
P
(χ2)
CDK7
     Low (0–160) 64 (43.8)  15 (10.3)  51 (34.9)  16 (11.0) <0.001
     High (161–300)  63 (15.3) 45 (10.9) 182 (44.1) 123 (29.8)   (56.3)
CycH
     Low (0–194)  81 (36.0)  31 (13.8)  74 (32.9)  39 (17.3) <0.001
     High (195–300)  68 (15.3) 47 (10.6) 197 (44.4) 132 (29.7)   (43.8)
MAT1
     Low (0–179)  84 (35.7) 30 (12.8)  97 (14.3)  24 (10.2) <0.001
     High (180–300)  38 (13.6) 27 (9.6) 109 (38.6) 106 (37.9)   (66.5)
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